Currently, the TGF-β signalling pathway is extensively used for prognosis prediction in various tumours, such as ovarian cancer, hepatocellular carcinoma, non-small-cell lung cancer (NSCLC), and colorectal cancer (47–50). This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.